Literature DB >> 8406435

Founder effect in a Belgian-Dutch fragile X population.

S Buyle1, E Reyniers, L Vits, K De Boulle, I Handig, F L Wuyts, W Deelen, D J Halley, B A Oostra, P J Willems.   

Abstract

For many years, the high prevalence of the fragile X syndrome was thought to be caused by a high mutation frequency. The recent isolation of the FMR1 gene and identification of the most prevalent mutation enable a more precise study of the fragile X mutation. As the vast majority of fragile X patients show amplification of an unstable trinucleotide repeat, DNA studies can now trace back the origin of the fragile X mutation. To date, de novo mutations leading to amplification of the CGG repeat have not yet been detected. Recently, linkage disequilibrium was found in the Australian and US populations between the fragile X mutation and adjacent polymorphic markers, suggesting a founder effect of the fragile X mutation. We present here a molecular study of Belgian and Dutch fragile X families. No de novo mutations could be found in 54 of these families. Moreover, we found significant (P < 0.0001) linkage disequilibrium in 68 unrelated fragile X patients between the fragile X mutation and an adjacent polymorphic microsatellite at DXS548. This suggests that a founder effect of the fragile X mutation also exists in the Belgian and Dutch populations. Both the absence of new mutations and the presence of linkage disequilibrium suggest that a few ancestral mutations are responsible for most of the patients with fragile X syndrome.

Entities:  

Mesh:

Year:  1993        PMID: 8406435     DOI: 10.1007/bf00244471

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  24 in total

1.  Fragile X founder effect?

Authors:  A Chakravarti
Journal:  Nat Genet       Date:  1992-07       Impact factor: 38.330

Review 2.  The fragile X: progress toward solving the puzzle.

Authors:  W T Brown
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

3.  The marker (X) syndrome: a cytogenetic and genetic analysis.

Authors:  S L Sherman; N E Morton; P A Jacobs; G Turner
Journal:  Ann Hum Genet       Date:  1984-01       Impact factor: 1.670

4.  Detection of linkage disequilibrium between the myotonic dystrophy locus and a new polymorphic DNA marker.

Authors:  H G Harley; J D Brook; J Floyd; S A Rundle; S Crow; K V Walsh; M C Thibault; P S Harper; D J Shaw
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

5.  Absence of expression of the FMR-1 gene in fragile X syndrome.

Authors:  M Pieretti; F P Zhang; Y H Fu; S T Warren; B A Oostra; C T Caskey; D L Nelson
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

6.  Evidence of founder chromosomes in fragile X syndrome.

Authors:  R I Richards; K Holman; K Friend; E Kremer; D Hillen; A Staples; W T Brown; P Goonewardena; J Tarleton; C Schwartz
Journal:  Nat Genet       Date:  1992-07       Impact factor: 38.330

7.  Segregation of the fragile X mutation from an affected male to his normal daughter.

Authors:  P J Willems; B Van Roy; K De Boulle; L Vits; E Reyniers; O Beck; J E Dumon; A Verkerk; B Oostra
Journal:  Hum Mol Genet       Date:  1992-10       Impact factor: 6.150

8.  Unstable DNA may be responsible for the incomplete penetrance of the myotonic dystrophy phenotype.

Authors:  P Shelbourne; R Winqvist; E Kunert; J Davies; J Leisti; H Thiele; H Bachmann; J Buxton; B Williamson; K Johnson
Journal:  Hum Mol Genet       Date:  1992-10       Impact factor: 6.150

9.  Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.

Authors:  J D Brook; M E McCurrach; H G Harley; A J Buckler; D Church; H Aburatani; K Hunter; V P Stanton; J P Thirion; T Hudson
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

Review 10.  Human genomic diversity in Europe: a summary of recent research and prospects for the future.

Authors:  L L Cavalli-Sforza; A Piazza
Journal:  Eur J Hum Genet       Date:  1993       Impact factor: 4.246

View more
  8 in total

1.  FMR1 in global populations.

Authors:  C B Kunst; C Zerylnick; L Karickhoff; E Eichler; J Bullard; M Chalifoux; J J Holden; A Torroni; D L Nelson; S T Warren
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

2.  Predisposition to the fragile X syndrome in Jews of Tunisian descent is due to the absence of AGG interruptions on a rare Mediterranean haplotype.

Authors:  T C Falik-Zaccai; E Shachak; M Yalon; Z Lis; Z Borochowitz; J N Macpherson; D L Nelson; E E Eichler
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

3.  Genetic diversity of the fragile X syndrome gene (FMR1) in a large Sub-Saharan West African population.

Authors:  Emmanuel K Peprah; Emily G Allen; Scott M Williams; Laresa M Woodard; Stephanie L Sherman
Journal:  Ann Hum Genet       Date:  2010-07       Impact factor: 1.670

Review 4.  Fragile X syndrome: the FMR1 CGG repeat distribution among world populations.

Authors:  Emmanuel Peprah
Journal:  Ann Hum Genet       Date:  2011-12-21       Impact factor: 1.670

5.  Closely linked cis-acting modifier of expansion of the CGG repeat in high risk FMR1 haplotypes.

Authors:  S Ennis; A Murray; G Brightwell; N E Morton; P A Jacobs
Journal:  Hum Mutat       Date:  2007-12       Impact factor: 4.878

6.  Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands.

Authors:  E M van Schothorst; J C Jansen; E Grooters; D E Prins; J J Wiersinga; A G van der Mey; G J van Ommen; P Devilee; C J Cornelisse
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

7.  Fragile X gene instability: anchoring AGGs and linked microsatellites.

Authors:  N Zhong; W Yang; C Dobkin; W T Brown
Journal:  Am J Hum Genet       Date:  1995-08       Impact factor: 11.025

8.  Haplotype Analysis of DXS548 and FRAXAC1 Microsatellite Loci in Iranian Patients with Fragile X Syndrome.

Authors:  Seyed Ahmad Aleyasin; Fatemeh Salamat; Mojgan Mirakhori
Journal:  Iran J Child Neurol       Date:  2018
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.